VCRE (Vicore Pharma Holding AB) 6-1 Month Momentum %: N/A% (As of Jul. 07, 2026)


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $15.03
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB 6-1 Month Momentum %?

Vicore Pharma Holding AB VCRE -7.54% 13 6-1 Month Momentum % is N/A% as of Jul. 07, 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 1,381 Biotechnology companies, Vicore Pharma Holding AB ranks better than 73.28% on this metric.

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-07-07), Vicore Pharma Holding AB's 6-1 Month Momentum % is N/A%.

The industry rank for Vicore Pharma Holding AB's 6-1 Month Momentum % or its related term are showing as below:

VCRE's 6-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -14.29
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Vicore Pharma Holding AB  (NAS:VCRE) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Vicore Pharma Holding AB 6-1 Month Momentum % Related Terms

VCRE
13GF Score
Vicore Pharma Holding AB VCRE
6-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB  (NAS:VCRE) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-1 Month Momentum % →
What does a 6-1 Month Momentum % of N/A% mean?
Vicore Pharma Holding AB (VCRE) has a 6-1 Month Momentum % of N/A% as of Jul. 07, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vicore Pharma Holding AB and its competitors. According to the industry distribution chart, Vicore Pharma Holding AB ranks #369 out of 1381 companies in the Biotechnology industry, placing it in the top 26.7%.
Is Vicore Pharma Holding AB's 6-1 Month Momentum % too high?
Vicore Pharma Holding AB's current 6-1 Month Momentum % is N/A%. Based on the distribution chart, Vicore Pharma Holding AB ranks #369 out of 1381 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's 6-1 Month Momentum % compare to ?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #369 out of 1381 companies for 6-1 Month Momentum %. This puts Vicore Pharma Holding AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current 6-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current 6-1 Month Momentum % of N/A%. The current 6-1 Month Momentum % is N/A%. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current 6-1 Month Momentum % is N/A% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.03
Price